GlassScriptPhysician profile
Naum Shaparin
NPI 1164615878
$69,548.31
in general payments reported to CMS, 2019-2025
28 companies · $3,502 in 2025
The $3,502 reported for 2025 was more than what 90% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $9,853 · 2021: $115 · 2022: $2,302 · 2023: $1,647 · 2024: $1,706 · 2025: $3,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,050 · Food and Beverage: $2,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,050.00 |
| Food and Beverage | $2,805.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $40,007.12 | 2019-2022 | |
| Acelrx Pharmaceuticals, INC. | $20,512.99 | 2019-2022 | |
| Becton, Dickinson and Company | $4,050.00 | 2023-2025 | Bd Intelliport |
| Boston Scientific Corporation | $2,041.98 | 2019-2025 | Wavewriter Alpha Prime 16, General - Therapies |
| Medtronic, INC. | $768.04 | 2021-2025 | Intellis Adaptivestim |
| Abbvie INC. | $223.76 | 2023-2025 | Botox, Ubrelvy |
| Mallinckrodt Enterprises LLC | $219.01 | 2019 | |
| Avanos Medical | $196.60 | 2019-2021 | |
| Cumberland Pharmaceuticals, INC. | $169.85 | 2019-2024 | Caldolor |
| Vertex Pharmaceuticals Incorporated | $137.60 | 2024-2025 | |
| Stimwave Technologies Incorporated | $135.41 | 2019-2022 | |
| Spr Therapeutics, INC | $128.14 | 2023 | Sprint Pns System |
| Relievant Medsystems, INC. | $125.84 | 2019 | |
| Heron Therapeutics, INC. | $122.35 | 2019-2023 | Zynrelef |
| Eagle Pharmaceuticals, INC. | $122.27 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $117.50 | 2020 | |
| Vertiflex, INC. | $102.24 | 2019 | |
| Abbott Laboratories | $80.20 | 2024 | Eterna |
| Medtronic USA, INC. | $56.41 | 2019-2020 | |
| Mml US, INC. | $42.06 | 2025 | Reactiv8 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.18 | 2019-2023 | Relistor |
| Palette Life Sciences, INC. | $31.21 | 2020 | |
| Saluda Medical Americas, INC. | $29.30 | 2024 | Evoke |
| Nevro Corp. | $28.12 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $25.87 | 2023 | Bridion |
| Flowonix Medical Incorporated | $21.63 | 2019 | |
| Allergan, INC. | $17.63 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naum Shaparin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.